The Match Out: Huge intra-day bounce as buyers emerge with force
James Gerrish
September 22, 2023
Here’s today’s The Match Out report from Market Matters’ James
Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
Here’s today’s The Match Out report from Market Matters’ James
S&P/ASX 200 (ASX:XJO) managed a 0.2% gain on Friday, overcoming
The S&P/ASX 200 (ASX: XJO) finished broadly flat on Tuesday
The Mesoblast Limited (ASX:MSB) share price is being crunched. It’s
The S&P/ASX 200 (ASX:XJO) continued its positive run on Wednesday
The S&P/ASX 200 (ASX: XJO) gained another 0.3% to begin
Shares in Mesoblast Limited (ASX: MSB) have taken a 21%
The Mesoblast Limited (ASX:MSB) share price is under the spotlight
Mesoblast Limited (ASX: MSB) shares have had a horrid twelve
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
